Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 17 / Drugs : 22 - (DrugBank : 10) / Drug target genes : 11 - Drug target pathways : 103

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Abrocitinib
   Peng Zhang
      2023   Early Phase 1   NCT06119490   China
Adipose derived stromal cells intravenously injected
   Assistance Publique - Hôpitaux de Paris
      2024   Phase 1/Phase 2   NCT04711200   France
Blood draw
   Joseph M. Still Research Foundation, Inc.
      2019   -   NCT04252651   United States
Clobetasol 0.05% ointment
   University of California, Davis
      2016   Phase 1/Phase 2   NCT02319616   United States
Daratumumab
   Hospices Civils de Lyon
      2025   Phase 1/Phase 2   NCT07110662   France
Etanercept
   Abe Riichirou
      2021   Phase 2   JPRN-jRCTs031210325   -
Etanercept 50 MG SC DAY 1 and DAY 4
   Vanderbilt University Medical Center
      2023   Phase 3   NCT02987257   United States
Harmonized supportive care
   Vanderbilt University Medical Center
      2023   Phase 3   NCT02987257   United States
Infliximab
   Loyola University
      2006   Phase 2   NCT00372723   United States
   Massachusetts Eye and Ear Infirmary
      2010   Phase 1/Phase 2   NCT01256489   United States
Intravenous immunoglobulin
   Nihon Pharmaceutical Co., Ltd
      2012   Phase 3   NCT01696500   Japan
Isotretinoin
   Massachusetts General Hospital
      2016   -   NCT02795143   United States
Methylprednisolone
   Morita Eishin
      2017   Phase 2   JPRN-jRCTs061180044   Germany;Japan;Taiwan
Palifermin
   Brett King
      2010   Phase 1/Phase 2   NCT02037347   United States
Prednisolone
   Morita Eishin
      2017   Phase 2   JPRN-jRCTs061180044   Germany;Japan;Taiwan
Recombinant granulocyte - colony stimulating factor
   University of Liege
      2016   Phase 4   NCT02739295   Belgium
Site specific standard OF care comparison
   Massachusetts General Hospital
      2030   -   NCT03585946   -
Tofacitinib
   Chang Gung Memorial Hospital
      2022   -   NCT06474078   Taiwan
   Peng Zhang
      2023   Early Phase 1   NCT06119490   China
Topical infliximab
   James Chodosh, MD, MPH
      2014   Phase 1/Phase 2   NCT02126020   Canada;United States